According to studies, unregulated skin-lightening products contain harmful substances, including mercury, that can pose ...
Harish suffered kidney damage after using a skin-whitening cream that had no labels or ingredients listed. Treated for ...
As skin-lightening creams and even the injectable glutathione are increasingly being used for skincare, there are concerns ...
Analysts at Wedbush lifted their Q4 2024 EPS estimates for shares of argenx in a report released on Monday, January 13th.
A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...
Initiate the third Cohort of the Phase 2 Basket study (WAL0921-02) in Rare glomerular kidney diseases, including focal segmental glomerulosclerosis (FSGS), treatment resistant minimal change disease ...
In fact, from Merck's $1.3 billion deal to GSK's $850 million investment, the "gold content" of Chinese companies' self-developed TCE bispecific antibodies has already been well proven. The new moves ...
competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune ...
(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...
Budoprutug is under clinical development by Climb Bio and currently in Phase II for Membranous Glomerulonephritis. According to GlobalData, Phase II drugs for Membranous Glomerulonephritis does not ...
Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...